Amyris & Genome Compiler Launch Testing Program for Pharma and Biotech Companies to Explore DNA Construction and Design Solutions

  EMERYVILLE and LOS ALTOS, Calif., (August 10, 2015) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and Genome Compiler Corp., a synthetic biology platform company, today announced the availability of an open testing program for pharma and biotech companies to explore DNA design and construction solutions. The two companies announced a collaboration agreement in…